Clinical trial · no report yet · Phase 2
NCT07475806
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- NCT07475806 ↗
- Recruiting
- Astellas Pharma Global Development, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 7 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Enfortumab Vedotin; Pembrolizumab
- Arms
- Enfortumab Vedotin with Pembrolizumab · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Overall clinical complete response (cCR) rate after treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator
- Bladder-intact event-free survival (BI-EFS) rate in participants who achieve cRC after 9 cycles of treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator
- Sponsor
- Astellas Pharma Global Development, Inc. with Pfizer
- Start
- Mar 12, 2026
- Primary completion
- Nov 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07475806 · updated Oct 20, 2026